🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ASCO25 Developmental Therapeutics CSS🔥 Jordi Remon insightfully dissects pro’s, cons & open questions on DELLI & timing of IO. Next steps: - DELLI: trials with chemo, engage regulators - Timing of IO: time cut-off, no. of infusions, too simple to be true? ASCO OncoAlert

🚨 Wow! #ASCO25 ASCO was absolutely massive! 10 NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

In our study, we focused on identifying features & biomarkers that may help physicians tailor the first-line treatment for these patients. Smoking history, PD-L1, baseline brain metastatic disease, and TP53 co-mutational status may be factors to consider vjoncology.com/video/6ogftj3k…

📌 Highlights of the Day III 🧬Breast Cancer - Local/Regional/Adjuvant ✨Jacqueline Sara Jeruss, MD,PhD ▪️EA1181 (CompassHER2 pCR) trial. 🔸 I-SPY2 trial. ▫️AXSANA / EUBREAST-03 / AGO-B-053 study. 🔹 SOFT and TEXT Trials. OncoAlert #OncoAlertAF #ASCO25

The landscape for radioligand therapies in oncology nature.com/articles/d4157… This article analyses the rapidly expanding landscape for radioligand therapies for cancer, including trends in technological advances and areas of application

Digital pathology and clinical multimodal AI again can predict treatment needs in prostate cancer, now with abiraterone in STAMPEDE at #ASCO25 #MedIQASCO25 ArteraAI in very high risk disease! Predictive and prognostic for MFS, PCSM.

🗣️Prostate Oral Abstract #ASCO25 👉Abst5001: Dr Nick James also on @Prof-Nick-James.bsky.social presenting #MMAI for benefit from ARPI in high risk M0 PCa #STAMPEDE 🤖Multimodal AI #MMAI algorithm (ArteraAI Prostate Test v1.2) High-risk M0 STAMPEDE (w/ H&E images& clinical data) >2/3 Risk Factors (T3-4,

#ASCO25 #melanomaorals A single dose of Neoadjuvant Pembro for clinical stage 2B and 2C was safe and did not delay surgery, all while it could have a decreased rate of positive SLNBs for some stage 2C melanomas with a potential benefit in RFS and DFMS

🔎Tailoring treatment in mCSPC w/ biomarkers? Evolving landscape beyond high vs low and synchronous vs metachronous disease ASCO ✅PSA nadir is strongly prognostic in IRONMAN - pending trial data (TRIPLE-SWITCH and A-DREAM if PSA >/0.2) to guide nadir in therapy decisions

IRAKLIA study shows on body delivery system is safe, effective and preferred by patients. Cool fearture that time of administration depends on tissue resistance. Called "escargot" in France! Less infusion/injection reactions (1.5 vs 25%) #ASCO25

Most expected #Arches 5 yr follow up data to be pro-forma @asco #ASCO25 But then this data popped up 👀 Less clear benefit of Enza+ADT in low volume #mCSPC Should this raise ?s for #mCSPC intensification w/#parp & #LU-psma Implications for over treating PSMA+ recurrence?

🗣️Prostate Oral Abstract #ASCO25 👉Abst5008: Dr Ana Aparicio presenting #CarboplatinCabazitaxelCetrelimab -> #Niraparib +/- Cetrelimab in AVPC on #C3NIRA n = 120 #AVPC (>1/9 criteria: small cell, visceral/bone only, >5cm bulky nodes, early CRPC, PSA <10, high LDH/CEA, loss

PRRT is a very effective for well-differentiated NETs but associated with a low risk of treatment related myeloid neoplasms ( t-MN ). If you are interested in learning more, this is the review for you... 😀 Bassam Sonbol Mrinal Patnaik yael kusne MD PhD erc.bioscientifica.com/view/journals/…

Impressive efficacy data from NEXICART-2 in AL #Amyloidosis at #ASCO25! Few thoughts: 1. With low plasma cell burden in relapsed/refractory AL, I do expect ~90-100% MRD-negative heme-CR rate with BCMA CAR T (The 3 VGPR/low-dFLC PRs will deepen into heme-CR with a bit more

Just a quick AI query gives us plenty of examples of non-profit systems acting poorly: 1. Wellstar Health System and Atlanta Medical Center (AMC) In April 2016 Wellstar paid Tenet 575 million dollars for five Atlanta hospitals, including AMC and its South Campus, both long-time

The most robust data post EVP in M1 bladder cancer by Michal Sternschuss MSKCC Carboplatin/gem was the commonest regimen #ASCO25 OncoAlert Results showed ⬆️ RRs than expected (50%) PFS =4.5 months & OS =11 months are good. 1st line gem/carbo OS was ~10 months previously?

Just in time as Darolutamide is now also U.S. FDA approved for mHSPC based off ARANOTE study - Ph III, metastatic (by bone scan or CT/MRI) hormone-sensitive prostate cancer. - rPFS NR (statistically significant) but OS (not statistically significant) #OncTwitter #MedTwitter

And related to this post, we just heard that FDA was granting Priority Review for R/R NPM1-Mutant AML #leusm cancernetwork.com/view/ziftomeni…

Congratulations Ali Arafa on developing the first prognostic blood-based PROTEOMIC biomarker for 177Lu-PSMA-617 efficacy, presented at ASCO ‘25. Masonic Cancer Center, University of Minnesota University of Minnesota meetings.asco.org/abstracts-pres…

Impressive results indeed for China base phase2 trial of BNT327 +chemo in pleural & peritoneal #mesothelioma #ASCO25